Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.

Eghbali M, Alaei-Shahmiri F, Hashemi-Madani N, Emami Z, Mostafavi L, Malek M, Khamseh ME

Advances in therapy4 Jan 2024Cited by 13 (Europe PMC)

PMID38172377DOI10.1007/s12325-023-02761-1PepBankPUB-38172377

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In Iranian adults with type 2 diabetes on liraglutide, median HbA1c reduction was -2.5% in optimal responders and -1.0% in suboptimal responders (P < 0.001).
In plain wordsIn Iranian adults with type 2 diabetes taking liraglutide, optimal responders lowered HbA1c more than suboptimal responders, by definition of the groups.
Peptide
Liraglutide
Outcome
DecreaseMedian HbA1c reduction in optimal versus suboptimal responders
Study
n = 233
Comparator
Suboptimal responders
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Median HbA1c reduction
−2.5%
optimal responders
Median HbA1c reduction
−1%
suboptimal responders
Source sentences
Summary
Median HbA1c reduction was - 2.5% in the optimal responder group compared with - 1.0% in the suboptimal responder group (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients received liraglutide 1.8 mg/day subcutaneously for 24 weeks.
Summary · context
In each category, subjects with HbA1c reduction greater than the median ΔHbA1c value for that group were defined as optimal responders.
Report a problemFND-3817237701
02HumanObservational studyOther
In Iranian adults with type 2 diabetes on liraglutide, rs10305420 T allele homozygosity was associated with optimal glycemic response (recessive model OR 3.28).
In plain wordsIn Iranian adults with type 2 diabetes taking liraglutide, a gene variant in the GLP-1 receptor was linked to a better blood sugar response.
Peptide
Liraglutide
Outcome
Not applicableGLP-1R rs10305420 T allele homozygosity and glycemic response
Study
n = 233
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
OR (recessive model)
3.28
rs10305420 T allele homozygosity
OR (codominant model)
2.52
rs10305420 T allele homozygosity
Source sentences
Summary
In genetic models, rs10305420 T allele homozygosity was associated with optimal glycemic response to liraglutide compared with heterozygous and wild-type homozygous states (recessive model: OR 3.28, 95% CI 1.41-7.65, P = 0.006; codominant model: OR 2.52, 95% CI 1.03-6.13, P = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients received liraglutide 1.8 mg/day subcutaneously for 24 weeks.
Summary · context
In each category, subjects with HbA1c reduction greater than the median ΔHbA1c value for that group were defined as optimal responders.
Report a problemFND-3817237702
03HumanObservational studyOther
In Iranian adults with type 2 diabetes on liraglutide, no significant association was found between the rs6923761 variant and HbA1c reduction.
In plain wordsIn Iranian adults with type 2 diabetes taking liraglutide, the rs6923761 gene variant was not linked to the size of HbA1c reduction.
Peptide
Liraglutide
Outcome
No significant changeGLP-1R rs6923761 and HbA1c reduction
Study
n = 233
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
No significant association was found between rs6923761 variant and HbA1c reduction.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients received liraglutide 1.8 mg/day subcutaneously for 24 weeks.
Summary · context
In each category, subjects with HbA1c reduction greater than the median ΔHbA1c value for that group were defined as optimal responders.
Report a problemFND-3817237703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.